Flinton Capital Management LLC increased its stake in PRA Health Sciences Inc (NASDAQ:PRAH) by 16.7% during the 4th quarter, Holdings Channel reports. The institutional investor owned 4,928 shares of the medical research company’s stock after buying an additional 704 shares during the quarter. Flinton Capital Management LLC’s holdings in PRA Health Sciences were worth $453,000 as of its most recent SEC filing.
Several other institutional investors also recently bought and sold shares of PRAH. Enlightenment Research LLC purchased a new stake in shares of PRA Health Sciences in the 4th quarter worth approximately $101,000. Gideon Capital Advisors Inc. bought a new position in PRA Health Sciences in the 3rd quarter valued at approximately $207,000. Group One Trading L.P. bought a new position in PRA Health Sciences in the 3rd quarter valued at approximately $220,000. Quantamental Technologies LLC bought a new position in PRA Health Sciences in the 4th quarter valued at approximately $221,000. Finally, Twin Tree Management LP lifted its position in PRA Health Sciences by 59.7% in the 3rd quarter. Twin Tree Management LP now owns 2,058 shares of the medical research company’s stock valued at $227,000 after acquiring an additional 769 shares in the last quarter. Institutional investors own 98.14% of the company’s stock.
PRAH has been the topic of several analyst reports. BidaskClub cut PRA Health Sciences from a “strong-buy” rating to a “buy” rating in a research report on Friday, November 16th. Zacks Investment Research cut PRA Health Sciences from a “buy” rating to a “hold” rating in a research report on Wednesday, January 2nd. ValuEngine cut PRA Health Sciences from a “buy” rating to a “hold” rating in a research report on Wednesday, January 2nd. Robert W. Baird upped their price objective on PRA Health Sciences from $119.00 to $122.00 and gave the company an “outperform” rating in a research report on Thursday, February 28th. Finally, SunTrust Banks upped their price objective on PRA Health Sciences to $120.00 and gave the company an “average” rating in a research report on Monday, March 4th. Five equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company. The stock presently has an average rating of “Buy” and an average price target of $113.22.
TRADEMARK VIOLATION NOTICE: This story was originally posted by Markets Daily and is the property of of Markets Daily. If you are reading this story on another publication, it was copied illegally and republished in violation of U.S. and international copyright laws. The legal version of this story can be viewed at https://www.themarketsdaily.com/2019/03/15/flinton-capital-management-llc-buys-704-shares-of-pra-health-sciences-inc-prah.html.
PRA Health Sciences Company Profile
PRA Health Sciences, Inc, a contract research organization, provides outsourced clinical development and data solution services to the biotechnology and pharmaceutical industries worldwide. The company operates in two segments, Clinical Research and Data Solutions. The Clinical Research segment offers product registration services, including clinical trial management, project management, regulatory affairs, therapeutic expertise, clinical operations, data and programming, safety and risk management, biostatistics and medical writing, quality assurance, and late phase services.
Featured Story: Benefits of owning preferred stock
Want to see what other hedge funds are holding PRAH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for PRA Health Sciences Inc (NASDAQ:PRAH).
Receive News & Ratings for PRA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PRA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.